An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 24 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 08 Jul 2011 Additional locations (France, Germany, Italy, England) added as reported by ClinicalTrials.gov.